BridgeBio Oncology Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
BBOT$2.20-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Balance Sheets
Conde nsed Consolidated Balance Sheets
(In thousands, except shares and per share data)
| September 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $76,479 | $373,687 |
| Short-term marketable securities | 117,390 | 51,773 |
| Receivables from related parties | 155 | 386 |
| Prepaid expenses and other current assets | 14,302 | 6,550 |
| Total current assets | 208,326 | 432,396 |
| Long-term marketable securities | 121,462 | — |
| Property and equipment, net | 815 | 956 |
| Operating lease right-of-use asset | 1,987 | 2,330 |
| Other non-current assets | 13,502 | 12,567 |
| Restricted cash | 132 | 132 |
| Total assets | $346,224 | $448,381 |
| Liabilities, Redeemable Convertible Preferred Stock, and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $10,261 | $1,374 |
| Accrued compensation and benefits | 5,267 | 5,746 |
| Accrued research and development liabilities | 32,681 | 25,951 |
| Accrued professional services | 1,652 | 674 |
| Payables to related parties | 232 | 534 |
| Operating lease liability, current | 571 | 522 |
| Other accrued liabilities | 362 | 240 |
| Total current liabilities | 51,026 | 35,041 |
| Operating lease liability, noncurrent | 1,810 | 2,244 |
| Total liabilities | 52,836 | 37,285 |
| Commitments and contingencies (Note 7) | ||
| Redeemable convertible preferred stock, $0.0001 par value; no shares authorized, issued and outstanding as of September 30, 2026 or December 31, 2025 | — | — |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of September 30, 2026 and December 31, 2025; no shares issued or outstanding as of September 30, 2026 or December 31, 2025, respectively | — | — |
| Common stock, $0.0001 par value; 500,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 80,234,557 and 79,991,768 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 8 | 8 |
| Additional paid-in capital | 784,378 | 767,639 |
| Accumulated deficit | (489,303) | (356,567) |
| Accumulated other comprehensive income (loss) | (1,695) | 16 |
| Total stockholders’ equity | 293,388 | 411,096 |
| Total liabilities, redeemable convertible preferred stock, and stockholders’ equity | $346,224 | $448,381 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.